Trial
NCT00809185
RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Case Comprehensive Cancer Center
Collaborators
National Cancer Institute (NCI)
Condition
Myelodysplastic Syndromes
Intervention
everolimus
Why stopped
slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-03-07